Synergistic Combination of ALK4:ActRIIB Heteromultimer with Emerging Technologies for Enhanced SMA Treatment
Legal Citation
Summary of the Inventive Concept
This inventive concept integrates the patented recombinant ALK4:ActRIIB heteromultimer with distinct emerging technologies, including AI, IoT, blockchain, and novel biomaterials, to create a more effective and personalized system for treating spinal muscular atrophy (SMA).
Background and Problem Solved
The original patent addressed the treatment of SMA using recombinant ALK4:ActRIIB heteromultimer. However, there remains a need to improve treatment efficacy, monitoring, and personalization. This inventive concept tackles these limitations by combining the heteromultimer with cutting-edge technologies to provide a more comprehensive and efficient SMA treatment system.
Detailed Description of the Inventive Concept
The inventive concept consists of four synergistic combinations: (1) a machine learning-based predictive model integrated with the recombinant ALK4:ActRIIB heteromultimer for optimizing treatment efficacy, (2) a wearable IoT device connected to a blockchain-based data storage system for monitoring treatment outcomes, (3) a novel biomaterial for sustained release of the heteromultimer, and (4) an AI-powered genomics analysis platform for personalized treatment. These combinations enable real-time monitoring, data-driven decision-making, and targeted therapy, ultimately leading to improved patient outcomes.
Novelty and Inventive Step
The novelty of this inventive concept lies in the unexpected integration of the patented recombinant ALK4:ActRIIB heteromultimer with emerging technologies, resulting in a more effective, personalized, and efficient SMA treatment system. The inventive step is the recognition of the synergistic potential of combining these distinct technologies to address the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different machine learning algorithms, varying IoT device configurations, or alternative biomaterials for sustained release. Variations may also involve integrating the heteromultimer with other emerging technologies, such as augmented reality or 5G networks, to further enhance SMA treatment.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of rare disease treatment and personalized medicine. The target market includes pharmaceutical companies, biotech firms, and healthcare providers seeking to improve SMA treatment outcomes and patient quality of life.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/1841 |
| A | A61 | A61K31/7125 |
| A | A61 | A61K38/18 |
| A | A61 | A61K45/06 |
| A | A61 | A61P21/00 |
| C | C07 | C07K14/71 |
| C | C12 | C12N15/113 |
| A | A61 | A61K38/179 |
| C | C07 | C07K2319/30 |
| C | C07 | C07K2319/32 |
| C | C12 | C12N2310/11 |
| C | C12 | C12N2320/31 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and medical therapeutics, specifically neuromuscular disorder treatment with a focus on genetic and protein-based interventions for spinal muscular atrophy (SMA). Requires expertise in molecular biology, protein engineering, medical device integration, and computational healthcare technologies
Person of Ordinary Skill (PHOSITA) Profile
A researcher or medical technologist with advanced degrees in biotechnology, molecular biology, or biomedical engineering, possessing comprehensive knowledge of genetic therapies, protein interactions, and emerging digital health technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring and predictive technologies with existing protein-based therapeutic approaches represents a natural progression in personalized medicine. The combination of the ALK4:ActRIIB heteromultimer with machine learning, IoT, and genomic analysis platforms follows established trends in precision healthcare technology. These technological extensions represent incremental improvements that leverage known computational methods to enhance existing therapeutic interventions.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,599 |
|---|---|
| Title | Compositions and methods for treating spinal muscular atrophy |
| Assignee(s) | ACCELERON PHARMA INC. |